Akt Inhibitor MK2206
Akt Inhibitor MK2206 is a pharmaceutical drug with 29 clinical trials. Currently 1 active trials ongoing. Historical success rate of 74.1%.
Success Metrics
Based on 20 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
20
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
71.4%
20 of 28 finished
28.6%
8 ended early
1
trials recruiting
29
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Clinical Trials (29)
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 29